SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

• Phase: Phase 4

Details

• Lead Sponsor: Clinical Alliance for Research & Education - Infectious Diseases, LLC.
• Collaborator: GlaxoSmithKline
• Treatments: Abacavir; Atazanavir Sulfate; Ritonavir

Criteria

Inclusion Criteria:

• Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen

• Viral load <50 copies/ml

Exclusion Criteria:

• Viral load >50 copies/ml

• Having taken more than one antiretroviral regimen